血府逐瘀浓缩丸防治43例冠心病冠脉内支架植入术后再狭？…

探讨血府逐瘀浓缩丸防治冠心病冠脉内支架植入术后再狭窄的临床疗效。方法：将８４例冠脉内支架植入术成功的冠心病患者随机分为西药常规治疗和加血府逐瘀浓缩丸组和西药常规治疗组，疗程均为６个月。追踪观察患者有无心绞痛复发，以及患者的血瘀症状和血瘀证候积分的变化，并通过心电图活动平板运动试验，运动－静息心肌断层是像追踪，冠状动脉造影复查评价再狭窄的发生。

Clinical Study on Effect of Concentrated Xuefu Zhuyu Pill on Restenosis of 43 Cases Coronary Heart Disease after Intracoronary Stenting

Objective: To explore the clinical effectiveness of concentrated Xuefu Zhuyu Pill (CXZP) on restenosis (RS) of coronary heart disease (CHD) after intracoronary stenting. Methods: Eighty four successful intracoronary stenting patients were randomly divided into conventional treatment group ( control group, 41 cases) and conventional treatment plus CXZP group (treated group, 43 cases). The follow up underwent for 6 months. Clinical symptom, change of blood stasis were observed. And occurrence of restenosis was estimated by ECG exercise treadmill testing, emission computed tomography (ECT) and coronary angiography (CAG). Results: The symptoms of blood stasis of treated group improved in the follow up significantly (P<0 01), and the integral of blood stasis were decreased significantly in the treated group vs the conventional treatment group (P<0 01). The recurrent angina pectoris rate of the treated group was lower than the conventional treatment group (P<0 01). The 61.9% of 84 patients reexamined the CAG in the follow up, and the lower restenosis rate (25.8%) in the treated group than in the conventional treatment group (32.1%,P=0.59). Conclusion: There is the trend that CXZP could prevent restenosis. Therefore, it is necessary to increase the cases for further study of CXZP on preventing restenosis.